ORENCIA (abatacept) for injection
ORENCIA is a brand-name prescription drug that’s FDA-approved to treat Adult Rheumatoid Arthritis, Juvenile Idiopathic Arthritis. . Brand Name: ORENCIA (abatacept) for injection for intravenous use injection, for subcutaneous use Initial U.S. Approval: 2005
Home | (abatacept) for injection
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient Enquiry under NPP.
ORENCIA (abatacept) for injection
Abatacept, sold under the brand name Orencia, is a medication used to treat autoimmune diseases like rheumatoid arthritis, by interfering with the immune activity of T cells.
ORENCIA is a prescription medicine that reduces signs and symptoms in:
adults with moderate to severe rheumatoid arthritis (RA), including those who have not been helped enough by other medicines for RA. ORENCIA may prevent further damage to your bones and joints and may help your ability to perform daily activities. In adults, ORENCIA may be used alone or with other RA treatments other than tumor necrosis factor (TNF) antagonists.
children and adolescents 6 years of age and older with moderate to severe polyarticular juvenile idiopathic arthritis (JIA). ORENCIA may be used alone or with methotrexate.
Active ingredient: abatacept. Intravenous inactive ingredients: maltose, monobasic sodium phosphate, sodium chloride for administration
Abatacept was developed by Bristol-Myers Squibb and is licensed in the United States for the treatment of rheumatoid arthritis in the case of inadequate response to anti-TNFα therapy. Abatacept received approval from the FDA in 2005. Abatacept is used to treat adults with moderate to severe rheumatoid arthritis (RA) as a second-line agent, and as a first-line agent for people whose RA is severe and rapidly progressing. It also used to treat psoriatic arthritis and juvenile idiopathic arthritis.
Drug (Brand / Generic): ORENCIA / abatacept
Current Indications: Adult Rheumatoid Arthritis, Juvenile Idiopathic Arthritis.
Marketed by:: Bristol-Myers Squibb Company
Approval Date: 2005
Dosage forms and strengths of ORENCIA (abatacept).
1. 250 mg lyophilized powder in a single-use vial for intravenous infusion. 2. 125 mg/mL solution in a single-dose prefilled syringe
Find Reference Updates
Alleviare Life Sciences
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “ ORENCIA (abatacept) for injection ”. Confirmation of the order for ORENCIA (abatacept) for injection will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
Get Access to Treatment – ORENCIA
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha